Previous close | 16.15 |
Open | 16.07 |
Bid | 16.02 x 100 |
Ask | 16.10 x 100 |
Day's range | 15.88 - 16.22 |
52-week range | 12.22 - 16.86 |
Volume | |
Avg. volume | 711,882 |
Market cap | 1.008B |
Beta (5Y monthly) | 0.57 |
PE ratio (TTM) | 7.21 |
EPS (TTM) | 2.23 |
Earnings date | 31 July 2024 - 05 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 08 Sept 2015 |
1y target est | 16.00 |
Strong Performance with Significant Growth in Net Product Revenue
Innoviva ( NASDAQ:INVA ) First Quarter 2024 Results Key Financial Results Revenue: US$77.5m (up 1.5% from 1Q 2023). Net...
BURLINGAME, Calif., May 08, 2024--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the first quarter ended March 31, 2024, and highlighted select corporate achievements.